E-LIB Suche - Ergebnisse für: Dispenzieri, A.

1

Daratumumab, carfilzomib, and pomalidomide for the treatmen..:

Vaxman, I ; Kumar, S. K ; Buadi, F...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229532/. , 2023

Link: http://www.ncbi.nlm.nih...

2

Daratumumab, carfilzomib, and pomalidomide for the treatmen..:

I. Vaxman ; S. K. Kumar ; F. Buadi...
https://doi.org/10.1038/s41408-023-00859-x. , 2023

Link: https://doi.org/10.1038/..

3

P884: POTENTIAL BENEFIT OF POST-TRANSPLANT DOXYCYCLINE IN A..:

N. Abdallah ; A. Dispenzieri ; E. Muchtar...
http://journals.lww.com/10.1097/01.HS9.0000846412.15297.aa. , 2022

Link: https://doi.org/10.1097/..

4

P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB..:

Vaxman, I ; Kumar, S ; buadi, F...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430574/. , 2022

Link: http://www.ncbi.nlm.nih...

5

Outcomes by Cardiac Stage in Patients With Newly Diagnosed ..:

Minnema, MC ; Dispenzieri, A ; Merlini, G...
https://discovery.ucl.ac.uk/id/eprint/10162975/1/1-s2.0-S2666087322003957-main.pdf. , 2022

Link: https://discovery.ucl.ac..

6

P884: POTENTIAL BENEFIT OF POST-TRANSPLANT DOXYCYCLINE IN A..:

Abdallah, N ; Dispenzieri, A ; Muchtar, E...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430486/. , 2022

Link: http://www.ncbi.nlm.nih...

7

P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB..:

I. Vaxman ; S. Kumar ; F. buadi...
http://journals.lww.com/10.1097/01.HS9.0000846732.06415.be. , 2022

Link: https://doi.org/10.1097/..

8

Long-term safety and efficacy of patisiran for hereditary t..:

Adams, D ; Polydefkis, M ; González-Duarte, A...
https://discovery.ucl.ac.uk/id/eprint/10117722/3/Gillmore_LANCETNEUROL-D-20-00074%20accepted%20version.pdf. , 2021

Link: https://discovery.ucl.ac..

9

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/ SNMMI expert consensus rec..:

Dorbala S ; Ando Y ; Bokhari S...
info:eu-repo/semantics/altIdentifier/pmid/34196222. , 2021

Link: https://hdl.handle.net/1..

10

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomy..:

Nativi-Nicolau J ; Siu A ; Dispenzieri A...
info:eu-repo/semantics/altIdentifier/pmid/34729526. , 2021

Link: https://hdl.handle.net/1..

11

Tissue biopsy for the diagnosis of amyloidosis: experience ..:

Benson, MD ; Berk, JL ; Dispenzieri, A...
https://discovery.ucl.ac.uk/id/eprint/10138636/1/Tissue%20biopsy%20for%20the%20diagnosis%20of%20amyloidosis%20experience%20from%20some%20centres.pdf. , 2021

Link: https://discovery.ucl.ac..

12

Serum BCMA levels predict outcomes in MGUS and smoldering m..:

A. Visram ; C. Soof ; S. V. Rajkumar...
https://doi.org/10.1038/s41408-021-00505-4. , 2021

Link: https://doi.org/10.1038/..

13

Association between Choroidal Characteristics and Systemic ..:

Mano, F ; Dispenzieri, A ; Kusaka, S...
https://discovery.ucl.ac.uk/id/eprint/10129425/3/Keane_Association%20Between%20Choroidal%20Characteristics%20and%20Systemic%20Severity%20in%20Amyloidisis_AAM.pdf. , 2021

Link: https://discovery.ucl.ac..

14

"Real-life" data of the efficacy and safety of belantamab m..:

Vaxman, I ; Abeykoon, J ; Dispenzieri, A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651684/. , 2021

Link: http://www.ncbi.nlm.nih...

15

"Real-life" data of the efficacy and safety of belantamab m..:

I. Vaxman ; J. Abeykoon ; A. Dispenzieri...
https://doi.org/10.1038/s41408-021-00592-3. , 2021

Link: https://doi.org/10.1038/..